RABEP2

Across TCGA pan-cancer cohorts, RABEP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RABEP2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RABEP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RABEP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where RABEP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	1.000	0.721	.001	24	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	19	view →
CCRCC	DFS	Tertile	All	0.686	1.000	.007	13	view →
PDAC	OS	Quartile	III,IV	0.977	0.330	.024	7	view →
HNSC	OS	Median	IV	0.636	0.820	.049	1	view →
LSCC	DFS	Median	III,IV	0.450	0.844	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RABEP2–UCEC (DFS)

Open the UCEC breakdown →